Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: A retrospective analysis

Gastrointestinal Cancer Research

Volumn 4, Issue 5-6, 2011, Pages 155-160

  Eckmann, Karen R ^a   Patel, Dina K ^a   Landgraf, Andrea ^a   Slade, Julian H ^a   Lin, E ^a   Kaur, Harmeet ^a   Loyer, Evelyne ^a   Weatherly, Jacqueline M ^a   Javle, Milind ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; ERLOTINIB; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; ANEMIA; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; HILAR CHOLANGIOCARCINOMA; HUMAN; INTRAHEPATIC CHOLANGIOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84856864153     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. De Groen PC, Gores GJ, LaRusso NF, et al: Biliary tract cancers. New Engl J Med 341: 1368-1378, 1999
2. Chamberlain RS, Blumgart LH: Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol 7(1):55-66, 1999
3. Bartlett DL: Intrahepatic cholangiocarcinoma: a worthy challenge. Cancer J 15:255-256, 2009
4. Welzel TM, McGlynn KA, Hsing AW, et al: Impact of classification of hilar cholangiocarcinomas (klatskin tumors) on the incidence of intraand extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 98(12):873-875, 2006
5. Cardinale V, Semeraro R, Torrice A, et al: Intrahepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2(11):407-416, 2010
6. Hezel AF, Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 13:415-423, 2008
7. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Hepatobiliary cancers. v. 1.2011
8. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med 362:1273-1281, 2010
9. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896-902, 2007
10. Farrell JJ, Elsaleh H, Garcia M, et al: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1): 187-195, 2009
11. Okazaki T, Javle M, Tanaka M, et al: Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 16(1):320-329, 2010
12. Endo I, Gonen M, Yopp AC, et al: Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248:84-96, 2008
13. Chauffert B, Mornex F, Bonnetain, F, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU, and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Ann Oncol 19(9):1592-1599, 2008
14. Huguet F, Andre T, Hammel P, et al: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25(3):326-331, 2007
15. Nehls O, Oettle H, Hartmann JT, et al: Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98(2):309-315, 2008
16. Yoshikawa D, Ojima H, Iwasaki M, et al: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98(2):418-425, 2008
17. Gruenberger B, Schueller J, Heubrandtner U, et al: Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 11(12):1142-1148, 2010
18. Zhu AX, Meyerhardt JA, Blaszkowsy LS, et al: Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 11(1):48-54, 2010
19. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24(19):3069-3074, 2006